United States - English - NLM (National Library of Medicine)

auromedics pharma llc - hydroxyprogesterone caproate (unii: 276f2o42f5) (hydroxyprogesterone - unii:21807m87j2) - hydroxyprogesterone caproate injection, usp is indicated in non-pregnant women: for the treatment of advanced adenocarcinoma of the uterine corpus (stage iii or iv); in the management of amenorrhea (primary and secondary) and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer; as a test for endogenous estrogen production and for the production of secretory endometrium and desquamation. hydroxyprogesterone caproate is contraindicated in patients with known or suspected carcinoma of the breast, other hormone-sensitive cancer, or history of these conditions; undiagnosed abnormal vaginal bleeding; liver dysfunction or disease; missed abortion, and in those with a history of hypersensitivity to the drug. hydroxyprogesterone caproate is also contraindicated as a diagnostic test for pregnancy and in patients with current or history of thrombotic or thromboembolic disorders.

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - hydroxyprogesterone caproate (unii: 276f2o42f5) (hydroxyprogesterone - unii:21807m87j2) - hydroxyprogesterone caproate is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. the effectiveness of hydroxyprogesterone caproate injection is based on improvement in the proportion of women who delivered < 37 weeks of gestation. there are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity. limitation of use: while there are many risk factors for preterm birth, safety and efficacy of hydroxyprogesterone caproate injection has been demonstrated only in women with a prior spontaneous singleton preterm birth. it is not intended for use in women with multiple gestations or other risk factors for preterm birth. do not use hydroxyprogesterone caproate injection in women with any of the following conditions:  - current or history of thrombosis or thromboembolic disorders - known or suspected breast cancer, other hormone-sensitive cancer, or

United States - English - NLM (National Library of Medicine)

mylan institutional llc - hydroxyprogesterone caproate (unii: 276f2o42f5) (hydroxyprogesterone - unii:21807m87j2) - hydroxyprogesterone caproate injection is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. the effectiveness of hydroxyprogesterone caproate injection is based on improvement in the proportion of women who delivered < 37 weeks of gestation. there are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity. limitation of use: while there are many risk factors for preterm birth, safety and efficacy of hydroxyprogesterone caproate injection has been demonstrated only in women with a prior spontaneous singleton preterm birth. it is not intended for use in women with multiple gestations or other risk factors for preterm birth. do not use hydroxyprogesterone caproate injection in women with any of the following conditions:   hydroxyprogesterone caproate is indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a his

United States - English - NLM (National Library of Medicine)

lsne, inc - hydroxyprogesterone caproate (unii: 276f2o42f5) (hydroxyprogesterone - unii:21807m87j2) - hydroxyprogesterone caproate injection is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. the effectiveness of hydroxyprogesterone caproate injection is based on improvement in the proportion of women who delivered < 37 weeks of gestation. there are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity. limitation of use : while there are many risk factors for preterm birth, safety and efficacy of hydroxyprogesterone caproate injection has been demonstrated only in women with a prior spontaneous singleton preterm birth. it is not intended for use in women with multiple gestations or other risk factors for preterm birth. do not use hydroxyprogesterone caproate injection in women with any of the following conditions: - current or history of thrombosis or thromboembolic disorders - known or suspected breast cancer, other hormone-sens

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ranvet pty. limited - hydroxyprogesterone caproate - parenteral liquid/solution/suspension - hydroxyprogesterone caproate steroid-progestin active 100.0 mg/ml - endocrine system - horse mare (female) | female horse - anabolic steroid | abortion threat | androgenic properties | bone repair | catabolic complications | convalescence | erythropoietic activity | geriatric therapy | improve appetite | male sexual characterisitics | muscle development | non-virilising anabolic | pathophysiological process | protein and mineral anabolic | skeletal conditions | tissue breakdown | tissue repair | virilising anabolic

United States - English - NLM (National Library of Medicine)

amag pharmaceuticals, inc. - hydroxyprogesterone caproate (unii: 276f2o42f5) (hydroxyprogesterone - unii:21807m87j2) - hydroxyprogesterone caproate 250 mg in 1 ml - makena is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. the effectiveness of makena is based on improvement in the proportion of women who delivered < 37 weeks of gestation. there are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity. limitation of use : while there are many risk factors for preterm birth, safety and efficacy of makena has been demonstrated only in women with a prior spontaneous singleton preterm birth. it is not intended for use in women with multiple gestations or other risk factors for preterm birth. do not

New Zealand - English - Ministry for Primary Industries

zoetis new zealand limited - hydroxyprogesterone caproate - hydroxyprogesterone caproate 250 g/litre - endocrine agent (hormone)

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ranvet pty. limited - hydroxyprogesterone caproate - unknown - hydroxyprogesterone caproate steroid-progestin active 0.0 - active constituent

India - English - Central Drugs Standard Control Organization

zydus (g.rem) - hydroxyprogesterone caproate - inj - 250mg/ml - 1 - hydroxyprogesterone - oestrogens & progesterones & related synthetic drugs - habitual abortion, imminent abortion, infertility due to corpus luteum insufficiency, primary & secondary amenorrhea

India - English - Central Drugs Standard Control Organization

zydus (g.rem) - hydroxyprogesterone caproate - inj - 500mg/2ml - 1 - hydroxyprogesterone - oestrogens & progesterones & related synthetic drugs - habitual abortion, imminent abortion, infertility due to corpus luteum insufficiency, primary & secondary amenorrhea